1Eberhard DA,Johnson BE,Amler LC,et al.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with nonsmall-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J].J Clin Oncol,2005,23(25):5900-5909.
2Hirsch FR,Varella-Garcia M,Bunn PA Jr,et al.Epidermal growth factor receptor in non-small-cell lung carcinomas:correlation between gene copy number and protein expression and impact on prognosis[J]. J Clin Oncol,2003,21 (20):3798-3807.
3Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009,361 (10):947-957..
4Massarelli E,Varella-Garcia M,Tang X,et al.KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].Clin Cancer Res,2007,13:2890-2896.
5Kwak EL,Bang Y J,Camidge DR,et al.Anaplastic lymphomn kinase inhibition in non small cell lung cancer[J].N Engl J Med,2010,363:1693-1703.
6Johnson DH,Fehrenhacher L,Novotny WF,et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic nonsmall-cell lung cancer[J].J Clin Oncol,2004,22:2184-2191.
7Scagliotti GV,Parikh P,yon Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol,2008,26:3543-3551.
8Blumenschein GR Jr,Gatzemeier U,Fossella F,et al:Phase Ⅱ,multicenter,uncontrolled trial of single-gent sorafenib in patients with relapsed or refractory,advanced non small cell lung cancer[J].J Clin Oncol,2009,27:4274-4280.
9Dennis A.Wigle.Personalized therapy for non-small cell lung cancer:hype or clinical reality[J] ? Semin Thorac Cardiovasc Surg,2011,23 (1):30-35.
10Klastersky J,Awada A.Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC)[J].Crit Rev Oncol Hematol,2011.[Epub ahead of print].
6Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl ]" Med, 2002, 346(2): 92-98.
7Ozkan Y, Yardim-Akaydin S, Firat HA, et al. Usefulness of homocysteine as a cancer marker: total thiol compounds and folate levels in untreated lung cancer patients[J]. Anticancer Res, 2007, 27(2): 1185-1189.
8Kohaar I, Kumar J, Thakur N, et al. Homocysteine levels are associated with cervical cancer independent of methylene tetrahydrofolate reductase gene (MTHFR) polymorphisms in Indian population[J]. Biomarkers, 2010, 15(1): 61-68.
9Hanagiri T, Sugaya M, Takenaka M, et al. Preoperative tSY tKA zi-I and CEA as prognostic factors in patients with stage I non-small cell lung cancer[J]. Lung Cancer, 2011, 74(1): 112-117.
10Cedrs S, Nufiez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J]. Clin Lung Cancer, 2011, 12(3): 172-179.
